JAMA Cardiology

OCTOBER 1, 2024

This randomized clinical trial investigates the feasibility, safety, and efficacy of endovascular right-sided splanchnic nerve ablation for volume management in heart failure with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 68

Preserved Ejection Fraction Ablation Heart Failure 68

DAIC

MARCH 5, 2024

Biosense Webster Study Supports Low and Zero Fluoroscopy Workflow as Safe, Effective Alternative to Conventional Catheter Ablation 5. Henry Ford Health Heart Failure Patient First in Michigan to Receive Breakthrough Device 6. Machine Learning Informs a New Tool to Guide Treatment for Acute Decompensated Heart Failure 8.

Heart Failure 111

Heart Failure Atrial Fibrillation Interventional Cardiology Heart Valves 111

American College of Cardiology

FEBRUARY 19, 2025

Atrial fibrillation catheter ablation (AFCA) improved clinical outcomes compared with medical treatment alone, and early AFCA was associated with better outcomes than late AFCA, particularly decreased risk of heart failure (HF) hospitalization and atrial fibrillation (AFib) recurrence.

AFIB 64

AFIB Ablation Atrial Fibrillation Outcomes 64

Frontiers in Cardiovascular Medicine

JANUARY 28, 2024

Introduction A high recurrence rate of atrial fibrillation was monitored after catheter ablation for persistent atrial fibrillation. Patients will be randomized to (1) receive the standard treatment strategy plus sacubitril/valsartan titration, or (2) receive the standard treatment strategy without taking sacubitril/valsartan.

Atrial Fibrillation 64

Atrial Fibrillation Heart Failure Ablation Electrocardiogram 64

Frontiers in Cardiovascular Medicine

JANUARY 16, 2024

Introduction Catheter ablation is an effective and safe strategy for treating atrial fibrillation patients. Nevertheless, studies on the long-term outcomes of catheter ablation in patients with dilated cardiomyopathy are limited. Among the catheter ablation group, 58.7% ( n  = 27) had persistent atrial fibrillation.

Atrial Fibrillation 64

Atrial Fibrillation Ablation Cardiomyopathy Heart Failure 64

Medical Xpress - Cardiology

SEPTEMBER 2, 2024

2 at this year's ESC Congress 2024.

Atrial Fibrillation 40

Atrial Fibrillation Heart Failure Ablation Tachycardia 40

HeartRhythm

NOVEMBER 7, 2024

Predicting the anticipated benefit and selecting the optimal timing of catheter ablation of recurrent ventricular tachycardia (VT) in patients with severe heart failure (HF) can be challenging.

Heart Failure 45

Heart Failure Ablation Document Tachycardia 45

DAIC

JUNE 4, 2024

American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged 3.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Peripheral Arterial Disease Heart Failure Atrial Fibrillation 105

Journal of Clinical Investigation - Cardiology

DECEMBER 15, 2023

Heart failure with preserved ejection fraction (HFpEF) is a widespread syndrome with limited therapeutic options and poorly understood immune pathophysiology. Notably, selective ablation of XBP1 in T cells enhanced their persistence in the heart and lymphoid organs of mice with preclinical HFpEF.

Preserved Ejection Fraction 75

Preserved Ejection Fraction Heart Failure Obesity Ablation 75

HeartRhythm

APRIL 30, 2024

Catheter Ablation for Atrial Fibrillation (AFib) in heart failure is now a class I indication for patients with heart failure. Evidence supports the relationship between obesity and the incidence and recurrence of Afib.

Atrial Fibrillation 40

Atrial Fibrillation Heart Failure Obesity Ablation 40

HeartRhythm

JANUARY 6, 2025

Atrial fibrillation (AF) is a common arrhythmia in patients with heart failure (HF). Catheter ablation of AF has been proven to be an effective therapeutic option for AF management in HF, particularly in heart failure with reduced ejection fraction (HFrEF) [2, 3].

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

Circulation

OCTOBER 13, 2024

Circulation, Volume 150, Issue 16 , Page 1220-1222, October 15, 2024.

Atrial Fibrillation 81

Atrial Fibrillation Heart Failure Ablation Circulation 81

HeartRhythm

SEPTEMBER 25, 2024

Atrial fibrillation (AF) is a common reversible cause of worsening left ventricular ejection fraction (LVEF) in patients with heart failure. Guidelines propose a class 1 recommendation for AF catheter ablation (CA) in patients with heart failure with reduced ejection fraction1,2.

Atrial Fibrillation 40

Atrial Fibrillation Heart Failure Ablation 40

HCPLive

APRIL 26, 2024

A meta-analysis of 12 trials suggests catheter ablation for atrial fibrillation reduces heart failure events in HFrEF patients but not in HFpEF.

Ablation 59

Ablation Atrial Fibrillation AFIB Heart Failure 59

HeartRhythm

OCTOBER 21, 2024

Clinical outcomes among patients with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) treated with catheter ablation (CA) versus antiarrhythmic therapy (AAT) are not well-known.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

HeartRhythm

APRIL 30, 2024

Catheter ablation (CA) for atrial fibrillation (AF) and heart failure with reduced ejection fraction <40% (HFrEF) is associated with improved outcomes. The patient characteristics, AF effect on quality-of-life questionnaire (AFEQT), and ablation strategies performed remains uncertain in those with and without HFrEF.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Heart Failure Quality of Life 40

HeartRhythm

APRIL 30, 2024

Catheter ablation for ventricular tachycardia (VT) has been shown to decrease the risk of VT recurrence and hospitalization. However, a critical gap exists in national-level data assessing its impact on hospital outcomes in patients with acute heart failure with reduced ejection fraction (HFrEF).

Heart Failure 40

Heart Failure Tachycardia Ablation Hospital 40

HeartRhythm

APRIL 30, 2024

The efficacy of catheter ablation as a treatment approach for patients with concurrent atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) has been inadequately investigated.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

Journal of Cardiovascular Electrophysiology

AUGUST 7, 2023

Abstract A vast amount of now well-established clinical and epidemiological data indicates a close, interdependent, and symbiotic association between atrial fibrillation (AF) and heart failure (HF). whether ablation is mandatory or pointless in patients who have HF).

Atrial Fibrillation 40

Atrial Fibrillation Heart Failure Ablation Outcomes 40

European Journal of Heart Failure

FEBRUARY 25, 2025

Overview of the study population and effects observed after catheter ablation for atrial fibrillation. Herein we describe the effects of catheter ablation on AF burden, arrhythmia recurrences, and ventricular function in end-stage HF. to 39.18.3% ( p <0.001) following ablation. PVI, pulmonary vein isolation.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Heart Failure Arrhythmia 40

HeartRhythm

AUGUST 18, 2024

The impact of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on atrial fibrillation (AF) recurrence outcomes and adverse cardiovascular outcomes in heart failure (HF) patients after AF ablation is unknown.

Atrial Fibrillation 40

Atrial Fibrillation Heart Failure Ablation Outcomes 40

HeartRhythm

APRIL 30, 2024

Most clinical trials have suggested that strictly controlling resting heart rate (RHR) lower than 110 beats per minute (bpm) even less than 100 bpm is beneficial. However, the degree to which rate control prior to catheter ablation influence is unclear especially in AF patients with heart failure (HF).

Heart Failure 40

Heart Failure Ablation Atrial Fibrillation 40

HeartRhythm

MAY 2, 2024

The optimal treatment for atrial fibrillation (AF) in patients with heart failure with reduced ejection fraction (HFrEF) remains unsettled.

Atrial Fibrillation 45

Atrial Fibrillation Heart Failure Ablation 45

HeartRhythm

APRIL 30, 2024

Previous studies have demonstrated significant morbidity and mortality in patients with heart failure (HF) with reduced ejection fraction (HFrEF), particularly with accompanying atrial fibrillation (AF).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

HeartRhythm

APRIL 30, 2024

Studies have suggested that early atrial fibrillation (AF) ablation is associated with improved outcomes. However, it is unknown whether these patterns hold for persistent AF among patients with heart failure with preserved ejection fraction (HFpEF). The majority of these studies evaluated paroxysmal AF cases.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

HeartRhythm

APRIL 30, 2024

Left atrial and pulmonary artery pressure (PAP) elevation can reflect severity and dynamic status of heart failure (HF) in HF with preserved ejection fraction (pEF). Atrial fibrillation (AF) worsens HFpEF progression and pump failure, but catheter ablation can restore rhythm control in this population.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

HeartRhythm

APRIL 14, 2024

The benefit of catheter ablation in patients with atrial fibrillation (AF) for patients with heart failure with preserved ejection fraction (HFpEF) remains uncertain.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

American College of Cardiology

MAY 20, 2024

Research covered topics such as outcomes for pediatric subcutaneous ICD implantation; procedural success rates and risk factors associated with catheter ablation for atrial tachyarrhythmias; comparing echocardiographic guidance during left atrial appendage occlusion (LAAO); and atrial fibrillation (AFib) ablation in patients with heart failure with (..)

Heart Rhythm 48

Heart Rhythm Pediatrics Ablation Atrial Fibrillation 48

American College of Cardiology

APRIL 24, 2024

The PRO portion of the currently featured PRO/CON debate between Dr. Brian Olshansky and Dr. John Mandrola presents a significant conundrum within the fields of electrophysiology and geriatric cardiology.

Atrial Fibrillation 55

Atrial Fibrillation Heart Failure Electrophysiology Ablation 55

HeartRhythm

MAY 2, 2024

The authors claim that their score identifies heart failure (HF) patients who benefit the most from atrial fibrillation (AF) ablation. in favour of ablation in the “high-risk group” and 0.41 However, the crude hazard ratio (HR) for the primary endpoint was 0.32 in the “low-risk group”.

Atrial Fibrillation 40

Atrial Fibrillation Heart Failure Ablation Outcomes 40

American College of Cardiology

JUNE 10, 2024

Splanchnic ablation for volume management (SAVM) in heart failure with preserved ejection fraction (HFpEF) was discussed as a late-breaking trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023 in Cleveland, Ohio.

Preserved Ejection Fraction 42

Preserved Ejection Fraction Ablation Heart Failure Article 42

HeartRhythm

APRIL 30, 2024

Electrical storm (ES) is associated with a high mortality, leads to recurrent hospitalization due to heart failure or ICD therapy deliveries. Ventricular tachycardia (VT) ablation has demonstrated efficacy in lowering VT recurrences but prompt ablation is challenging and the exact timing still unknown.

Heart Failure 40

Heart Failure Ablation Tachycardia Hospital 40

HeartRhythm

OCTOBER 18, 2024

The impact of comorbidity burden on outcomes of radiofrequency catheter ablation (RFCA) for atrial fibrillation (AF) in patients with heart failure and preserved ejection fraction (HFpEF) remains unclear.

Preserved Ejection Fraction 45

Preserved Ejection Fraction Ablation Atrial Fibrillation Heart Failure 45

HeartRhythm

NOVEMBER 27, 2024

The goals of the current scientific research on ventricular tachycardia (VT) ablation included studies to prove the benefit of early ablation on heart failure progression and mortality and the need to better characterize and treat heterogeneous deep VT substrates.

Tachycardia 40

Tachycardia Ablation Heart Failure Research 40

HeartRhythm

SEPTEMBER 24, 2024

Current data on outcomes of an initial strategy of catheter ablation versus advanced therapy in patients with severe HF and ES are limited.

Ablation 40

Ablation Heart Failure Outcomes 40

HeartRhythm

JUNE 23, 2024

Catheter ablation has become the most effective rhythm control strategy in treating atrial fibrillation (AF), preventing AF recurrence and delaying its progression to persistent AF better than antiarrhythmic drugs.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Ablation Atrial Fibrillation Heart Failure 40

HeartRhythm

MAY 2, 2024

To fully understand the predictive value of the CASTLE-HTx risk-score in relation to the benefits of catheter ablation in patients with end-stage heart failure (HF) and atrial fibrillation (AF), it is essential to distinguish between absolute and relative risk reduction. The observed hazard ratios (HR) favoring ablation of 0.32

Atrial Fibrillation 40

Atrial Fibrillation Heart Failure Ablation 40